Impact of the <scp>COVID</scp>‐19 pandemic on patients with myasthenia gravis: A survey of the Myasthenia Gravis Foundation of America <scp>MG</scp> patient registry
Andrés De León-Benedetti(Emory University), Ikjae Lee(Columbia University Irving Medical Center), Inmaculada Aban(National and Kapodistrian University of Athens), Tarrant McPherson(University of Alabama at Birmingham), Gary Cutter(Epilepsy Foundation), Michael Benatar(University of Miami), Volkan Granit(Biohaven Pharmaceuticals (United States))
Cited by 7
Related Papers
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
Recommendations from the national multiple sclerosis society clinical outcomes assessment task force
|Annals of Neurology|1997|368
Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis
|Annals of Neurology|2010|365